Last reviewed · How we verify
Menitorix
At a glance
| Generic name | Menitorix |
|---|---|
| Also known as | Combined Hib-MenC vaccine (GSK Biologicals)., Hib/MenC-TT, GSK Biologicals' combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine. |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Baby Vaccine Study (Sched3) (PHASE2)
- Hepatitis B Vaccination in Infants (PHASE4)
- Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (PHASE4)
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (PHASE3)
- Pertussis and Meningitis C Concomitant Vaccination in Adolescents (PHASE4)
- A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix (PHASE4)
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menitorix CI brief — competitive landscape report
- Menitorix updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI